Halozyme Therapeutics (HALO) has 20,784,949 shares of shorts outstanding as on August 15, 2016, with 19 days left to cover or roll them over. On Jul 29, 2016, the open interest of short positions was 21,873,954 shares. The stock has a decent trading volume of 1,092,022 shares daily. The marginal decrease in the short positions is by -5%, which amounts to -1,089,005 shares. Short positions are 19.2% of the available float. The short interest information was released on Wednesday Aug 24th after the market close.
Halozyme Therapeutics (NASDAQ:HALO): The stock opened at $10.11 on Wednesday but the bulls could not build on the opening and the stock topped out at $10.30 for the day. The stock traded down to $9.35 during the day, due to lack of any buying support eventually closed down at $9.42 with a loss of -6.73% for the day. The stock had closed at $10.10 on the previous day. The total traded volume was 1,604,224 shares.
In a related news, Stelzer Laurie, CFO of Halozyme Therapeutics Inc had purchased 10,000 shares on August 20, 2015 in a transaction. The price per share was $17.24 and the total amount of the disclosed transaction was $172,400.The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. This information is based on open market transaction at the market prices.
Halozyme Therapeutics, Inc. is a biotechnology company, which is focused on developing and commercializing oncology therapies that target the tumor microenvironment. The Companys development pipeline consists primarily of clinical-stage product candidates in oncology and diabetes. The product candidates in its pipeline are based on rHuPH20, a human recombinant hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid (HA). Its lead oncology program is PEGPH20 (PEGylated recombinant human hyaluronidase), a new molecular entity, under development for the systemic treatment of tumors that accumulate HA. The Company is in collaboration with pharmaceutical companies including, Roche, Pfizer, Janssen and Baxter for its drug delivery platform, ENHANZE, which enables biologics and small molecule compounds that are administered intravenously to be delivered subcutaneously.